{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEPLISAV-B%C2%AE",
    "query": {
      "intervention": "HEPLISAV-B®"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 43,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEPLISAV-B%C2%AE&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T05:52:46.038Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04000737",
      "title": "YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sorafenib+YIV-906",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib+placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yiviva Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2020-01-10",
      "completion_date": "2024-11-19",
      "has_results": false,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 4,
      "location_summary": "Flushing, New York • Lake Success, New York • New York, New York + 1 more",
      "locations": [
        {
          "city": "Flushing",
          "state": "New York"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04000737"
    },
    {
      "nct_id": "NCT03673462",
      "title": "Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy Volunteers (Meningococcal Infection)"
      ],
      "interventions": [
        {
          "name": "Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, Mumps, and Rubella Virus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Virus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 2797,
      "start_date": "2018-09-17",
      "completion_date": "2023-03-16",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03673462"
    },
    {
      "nct_id": "NCT01940471",
      "title": "Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HBeAg-positive Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TAF",
          "type": "DRUG"
        },
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "TDF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 875,
      "start_date": "2013-09-11",
      "completion_date": "2022-10-13",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01940471"
    },
    {
      "nct_id": "NCT00985426",
      "title": "Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "HEPLISAV-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 521,
      "start_date": "2009-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00985426"
    },
    {
      "nct_id": "NCT00734162",
      "title": "Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B Virus (HBV)"
      ],
      "interventions": [
        {
          "name": "Tenofovir disoproxil fumarate (TDF)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 106,
      "start_date": "2008-12",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2016-09-01",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Indianapolis, Indiana • Seattle, Washington",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00734162"
    },
    {
      "nct_id": "NCT04398706",
      "title": "Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Immunisation",
        "Diphtheria Immunisation",
        "Tetanus Immunisation",
        "Pertussis Immunisation",
        "Hepatitis B Immunisation",
        "Haemophilus Influenzae Type b Immunisation",
        "Polio Immunisation",
        "Measles Immunisation",
        "Rubella Immunisation",
        "Varicella Immunisation",
        "Mumps Immunisation"
      ],
      "interventions": [
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, Mumps, and Rubella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus Vaccine, Live, Oral, Pentavalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine* [Recombinant] *as applicable",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "42 Days to 15 Months"
      },
      "enrollment_count": 852,
      "start_date": "2020-05-22",
      "completion_date": "2023-08-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 49,
      "location_summary": "Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04398706"
    },
    {
      "nct_id": "NCT00426712",
      "title": "Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "1018 ISS immunostimulatory oligonucleotide with HBV surface antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2006-01",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 4,
      "location_summary": "Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Brooklyn Center",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426712"
    },
    {
      "nct_id": "NCT03547908",
      "title": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1/HBV Co-Infection"
      ],
      "interventions": [
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match DTG",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match F/TDF",
          "type": "DRUG"
        },
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "F/TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match B/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 244,
      "start_date": "2018-05-30",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 4,
      "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Berkley",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547908"
    },
    {
      "nct_id": "NCT00474526",
      "title": "A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Meningococcal ACWY Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP-IPV-HBV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 7-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HAV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR-V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "2 Months",
        "sex": "ALL",
        "summary": "2 Months to 2 Months"
      },
      "enrollment_count": 4545,
      "start_date": "2007-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2014-03-24",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 53,
      "location_summary": "Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more",
      "locations": [
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474526"
    },
    {
      "nct_id": "NCT00722332",
      "title": "Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis B",
        "Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "HepaGam B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cangene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9,
      "start_date": "2008-02",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2013-11-01",
      "last_synced_at": "2026-09-09T05:52:46.038Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00722332"
    }
  ]
}